Oxford BioDynamics Plc (OXBOF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oxford BioDynamics Plc (OXBOF) with AI Score 49/100 (Weak). Oxford BioDynamics Plc is a biotechnology company focused on discovering and developing epigenetic biomarkers. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Oxford BioDynamics Plc (OXBOF) Healthcare & Pipeline Overview
Oxford BioDynamics Plc leverages its EpiSwitch platform to discover and develop epigenetic biomarkers for disease prediction and treatment. The company operates in the biotechnology sector, offering diagnostic and prognostic tools like EpiSwitch CiRT and CST, primarily targeting the pharmaceutical and biotechnology industries internationally.
Investment Thesis
Oxford BioDynamics presents a high-risk, high-reward investment profile within the biotechnology sector. The company's proprietary EpiSwitch platform offers a unique approach to biomarker discovery with potential applications across various diseases. A key value driver is the successful commercialization of EpiSwitch CiRT, which could generate revenue through predicting patient response to immunotherapy. The company's ability to secure partnerships with pharmaceutical companies for biomarker discovery and drug development is also crucial. However, the company's negative profit and gross margins (-1018.5% and -561.6%, respectively) highlight financial challenges. Upcoming data releases from clinical studies using EpiSwitch and regulatory approvals for its diagnostic tests are potential catalysts. Investors should closely monitor the company's cash burn rate and ability to secure additional funding to sustain operations.
Based on FMP financials and quantitative analysis
Key Highlights
- EpiSwitch Platform: Proprietary technology for epigenetic biomarker discovery.
- EpiSwitch CiRT: Validated prognostic test for predicting response to checkpoint inhibitor immunotherapy.
- EpiSwitch CST: Advanced blood test for predicting COVID-19 severity in adults.
- Market Cap: $0.00B indicates the company is a micro-cap stock.
- Negative Profit Margin: -1018.5% signals significant losses and operational inefficiencies.
Competitors & Peers
Strengths
- Proprietary EpiSwitch platform for epigenetic biomarker discovery.
- Validated diagnostic tests like EpiSwitch CiRT and CST.
- Expertise in epigenetics and biomarker development.
- Potential for partnerships with pharmaceutical companies.
Weaknesses
- Negative profit and gross margins.
- Limited commercialization of products.
- Dependence on external funding.
- OTC market listing indicates higher risk.
Catalysts
- Upcoming: Data releases from clinical studies using EpiSwitch for biomarker discovery.
- Upcoming: Potential regulatory approvals for EpiSwitch CiRT and other diagnostic tests.
- Ongoing: Expansion of partnerships with pharmaceutical companies for drug development.
- Ongoing: Increasing adoption of EpiSwitch technology in personalized medicine.
- Ongoing: Development of new diagnostic tests for autoimmune diseases.
Risks
- Ongoing: Negative profit and gross margins raise concerns about financial sustainability.
- Potential: Competition from established players in genomics and proteomics.
- Potential: Regulatory hurdles for diagnostic tests.
- Potential: Failure to secure additional funding.
- Ongoing: Limited liquidity due to OTC market listing.
Growth Opportunities
- Expansion of EpiSwitch CiRT into new cancer types: The EpiSwitch CiRT test is currently focused on predicting response to checkpoint inhibitors in specific cancers. Expanding its application to other cancer types represents a significant growth opportunity. The global oncology market is projected to reach $286.6 billion by 2028, providing a large addressable market for CiRT and future diagnostic tests. Timeline: Ongoing clinical trials and validation studies are expected to support expansion over the next 2-3 years.
- Development of new diagnostic tests for autoimmune diseases: Autoimmune diseases represent a significant unmet medical need, and the EpiSwitch platform could be used to develop novel diagnostic tests. The global autoimmune disease diagnostics market is projected to reach $16.1 billion by 2027. Oxford BioDynamics could leverage its technology to capture a share of this market. Timeline: Research and development efforts are likely to span 3-5 years before a commercially viable product is available.
- Partnerships with pharmaceutical companies for drug development: Oxford BioDynamics can partner with pharmaceutical companies to use the EpiSwitch platform to identify biomarkers for drug development. This could generate revenue through licensing agreements, milestone payments, and royalties on sales of drugs developed using the company's biomarkers. The pharmaceutical industry spends billions of dollars annually on drug discovery and development, creating a substantial market for biomarker-based services. Timeline: Partnership agreements could be established within the next 1-2 years, with revenue generation dependent on the success of drug development programs.
- Geographic expansion into Asia and Europe: Oxford BioDynamics currently focuses on the United States and international markets. Expanding into Asia and Europe represents a growth opportunity, particularly in countries with advanced healthcare systems and a growing demand for personalized medicine. The Asia-Pacific diagnostics market is projected to be the fastest-growing region globally. Timeline: Expansion efforts could begin within the next 2 years, with a focus on establishing partnerships and distribution networks.
- Application of EpiSwitch technology to personalized medicine: The EpiSwitch platform can be used to develop personalized medicine approaches, tailoring treatment decisions to individual patients based on their epigenetic profiles. The personalized medicine market is growing rapidly, driven by advances in genomics and proteomics. Oxford BioDynamics can position itself as a leader in epigenetic-based personalized medicine. Timeline: Development of personalized medicine applications is a long-term effort, likely to span 5-10 years.
Opportunities
- Expansion of EpiSwitch CiRT into new cancer types.
- Development of new diagnostic tests for autoimmune diseases.
- Partnerships with pharmaceutical companies for drug development.
- Geographic expansion into Asia and Europe.
Threats
- Competition from established players in genomics and proteomics.
- Regulatory hurdles for diagnostic tests.
- Failure to secure additional funding.
- Uncertainty in the biotechnology industry.
Competitive Advantages
- Proprietary EpiSwitch platform: Provides a unique technology for epigenetic biomarker discovery.
- Validated diagnostic tests: EpiSwitch CiRT and CST have demonstrated clinical utility.
- Expertise in epigenetics: Oxford BioDynamics has a team of scientists with expertise in epigenetics and biomarker discovery.
- Partnerships with pharmaceutical companies: Provides access to resources and expertise for drug development.
About OXBOF
Oxford BioDynamics Plc, incorporated in 2007 and headquartered in Oxford, UK, is a biotechnology company specializing in the discovery and development of biomarkers. The company's core technology is EpiSwitch, a proprietary platform that identifies and validates chromosome conformation signatures for use as epigenetic biomarkers. These biomarkers are applied in medical testing kits, disease prediction, diagnosis, and treatment monitoring. The company's key products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a prognostic test designed to predict a patient's response to checkpoint inhibitor immunotherapy. Another product, EpiSwitch CST (Covid Severity Test), is a blood test aimed at predicting the severity of COVID-19 in adults. Additionally, Oxford BioDynamics offers the EpiSwitch Explorer Array Kit, which facilitates high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics primarily serves the pharmaceutical and biotechnology industries, focusing on developing tools that can improve drug development, clinical trials, and patient outcomes. The company operates both in the United States and internationally, seeking partnerships and collaborations to expand the reach of its EpiSwitch technology and biomarker portfolio.
What They Do
- Discovers epigenetic biomarkers using its proprietary EpiSwitch platform.
- Develops diagnostic and prognostic tests for various diseases.
- Offers the EpiSwitch CiRT test to predict response to cancer immunotherapy.
- Provides the EpiSwitch CST test for predicting COVID-19 severity.
- Offers the EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling.
- Partners with pharmaceutical companies for biomarker discovery and drug development.
Business Model
- Generates revenue through the sale of diagnostic and prognostic tests.
- Partners with pharmaceutical companies for biomarker discovery and drug development, earning licensing fees, milestone payments, and royalties.
- Offers services for high-resolution 3D genome profiling and biomarker discovery using the EpiSwitch Explorer Array Kit.
Industry Context
Oxford BioDynamics operates within the competitive biotechnology industry, which is characterized by rapid innovation and high regulatory hurdles. The market for biomarker discovery and diagnostics is growing, driven by the increasing demand for personalized medicine and targeted therapies. Companies like Oxford BioDynamics face competition from established players in genomics and proteomics, as well as other emerging biotechnology firms. The company's success depends on its ability to differentiate its EpiSwitch platform, secure regulatory approvals, and establish partnerships with pharmaceutical companies.
Key Customers
- Pharmaceutical companies seeking biomarkers for drug development.
- Biotechnology companies developing diagnostic and therapeutic products.
- Hospitals and clinics using diagnostic tests for patient care.
- Research institutions conducting studies on epigenetics and disease.
Financials
Chart & Info
Oxford BioDynamics Plc (OXBOF) stock price: Price data unavailable
Latest News
No recent news available for OXBOF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OXBOF.
Price Targets
Wall Street price target analysis for OXBOF.
MoonshotScore
What does this score mean?
The MoonshotScore rates OXBOF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Iain Gladstone Ross
Managing Director
Iain Gladstone Ross serves as the Managing Director of Oxford BioDynamics Plc, overseeing the company's operations and strategic direction. Information regarding his detailed career history and educational background is not available in the provided data. However, as Managing Director, he is responsible for guiding the company's biomarker discovery and diagnostic development efforts.
Track Record: As Managing Director, Iain Gladstone Ross manages 51 employees. Specific achievements and milestones under his leadership are not detailed in the provided data. His role is crucial in driving the commercialization of the EpiSwitch platform and securing partnerships to advance the company's growth.
OXBOF OTC Market Information
The OTC Other tier, where Oxford BioDynamics trades, represents the lowest tier of the OTC market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited financial disclosure requirements and may not meet minimum listing standards. This tier typically includes companies with higher risk profiles, including those that are thinly traded, distressed, or have limited operating history. Investors should exercise caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure: The lack of publicly available financial reports makes it difficult to assess the company's financial health.
- Low liquidity: Limited trading volume can lead to wider bid-ask spreads and greater price volatility.
- Higher risk of fraud or manipulation: OTC markets are subject to less regulatory oversight than major exchanges.
- Potential for delisting: Failure to meet minimum listing standards could result in delisting from the OTC market.
- Limited access to capital: OTC-listed companies may have difficulty raising capital through public offerings.
- Verify the availability of financial reports and assess the company's financial health.
- Research the company's management team and their track record.
- Understand the company's business model and competitive landscape.
- Assess the liquidity of the stock and the potential for price volatility.
- Review the company's regulatory filings and compliance history.
- Consult with a financial advisor before investing.
- Confirm the legitimacy of the company's operations and assets.
- Proprietary EpiSwitch platform suggests technological innovation.
- Development of diagnostic tests like EpiSwitch CiRT and CST indicates potential for commercialization.
- Partnerships with pharmaceutical companies could validate the company's technology.
- Headquarters in Oxford, UK, a hub for biotechnology research.
- Management team with experience in the biotechnology industry.
OXBOF Healthcare Stock FAQ
What does Oxford BioDynamics Plc do?
Oxford BioDynamics Plc is a biotechnology company that focuses on discovering and developing epigenetic biomarkers using its proprietary EpiSwitch platform. This platform analyzes chromosome conformation signatures to identify biomarkers for disease prediction, diagnosis, and treatment monitoring. The company's products include diagnostic tests like EpiSwitch CiRT for predicting response to cancer immunotherapy and EpiSwitch CST for predicting COVID-19 severity. Oxford BioDynamics also partners with pharmaceutical companies to develop biomarkers for drug development, positioning itself as a key player in personalized medicine.
What do analysts say about OXBOF stock?
As of 2026-03-17, a comprehensive analyst consensus on OXBOF is not available in the provided data. Given its micro-cap status and OTC listing, analyst coverage may be limited. Key valuation metrics such as P/E ratio (-0.25) and negative profit margins (-1018.5%) suggest the company is currently unprofitable. Growth considerations revolve around the successful commercialization of its EpiSwitch platform, regulatory approvals for its diagnostic tests, and partnerships with pharmaceutical companies. Investors should conduct their own due diligence and consider the risks associated with investing in a micro-cap OTC stock.
What are the main risks for OXBOF?
The main risks for Oxford BioDynamics Plc include its negative profit and gross margins, which raise concerns about its financial sustainability. Competition from established players in the biotechnology industry, particularly in genomics and proteomics, poses a threat. Regulatory hurdles for diagnostic tests and the potential failure to secure additional funding are also significant risks. Additionally, the company's OTC market listing indicates higher risk due to limited liquidity and disclosure requirements. Investors should carefully consider these risks before investing in OXBOF.
What are the key factors to evaluate for OXBOF?
Oxford BioDynamics Plc (OXBOF) currently holds an AI score of 49/100, indicating low score. Key strength: Proprietary EpiSwitch platform for epigenetic biomarker discovery.. Primary risk to monitor: Ongoing: Negative profit and gross margins raise concerns about financial sustainability.. This is not financial advice.
How frequently does OXBOF data refresh on this page?
OXBOF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven OXBOF's recent stock price performance?
Recent price movement in Oxford BioDynamics Plc (OXBOF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary EpiSwitch platform for epigenetic biomarker discovery.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider OXBOF overvalued or undervalued right now?
Determining whether Oxford BioDynamics Plc (OXBOF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying OXBOF?
Before investing in Oxford BioDynamics Plc (OXBOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited and may not be up-to-date.
- Analyst consensus is not available.
- OTC market listing indicates higher risk.